SCHEMBL1999431

SCHEMBL1999431

Cc1cc(N(C)S(=O)(=O)c2ccc(Cl)nc2)ccc1CN1CCN(C(=O)O)[C@@](C)(C(C)(C)C)C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.34
SMN1; SMN2 Q16637 5/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CYP2D6 P10635 1/20 0.34
MAPT P10636 2/20 0.33
LMNA P02545 3/20 0.32
STAT3 P40763 1/20 0.32
RAB9A P51151 1/20 0.32
HTT P42858 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPK1 P28482 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
RECQL P46063 1/20 0.31
SIRT2 Q8IXJ6 1/20 0.31
MCOLN3 Q8TDD5 1/20 0.30
PTPN22 Q9Y2R2 1/20 0.30
ATM Q13315 1/20 0.30
NR1H2 P55055 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1997573 0.89 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2MEN1KMT2ACYP2D6
SCHEMBL2002729 0.86 MLNR (0.36) ALDH1A1MEN1KMT2ACYP2D6MAPT
SCHEMBL1998238 0.83 MLNR (0.42) ALDH1A1MEN1KMT2ACYP2D6MAPT
SCHEMBL2851951 0.79 MGLL (0.41) ALDH1A1SMN1; SMN2MEN1KMT2ACYP2D6
SCHEMBL2003107 0.76 MLNR (0.47) KDM4E
SCHEMBL1997413 0.76 MLNR (0.42) MEN1KMT2ACYP2D6MAPTLMNA
SCHEMBL1999429 0.75 GPR119 (0.41)
SCHEMBL1996929 0.74 KDM4E (0.46) ALDH1A1SMN1; SMN2MEN1KMT2ACYP2D6
SCHEMBL2766195 0.73 MLNR (0.41) ALDH1A1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL1996027 0.73 S1PR1 (0.39) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964597-B2 Piperazinyl-sulfonamide derivatives useful in the treatment of GPR38 receptor mediated diseases GLAXO GROUP LIMITED (GB) 2011-06-21 US disclosed